Ratings Moves: MGM,...
Health Care: Drugs
Arqule Inc. (ARQL: NASDAQ)
$2.79 0.08 | 2.95%
05/23/13 - 01:25 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -10.87M | -10.76M | -30.13M | -36.14M |
| Operating Gains/Losses | -113.00K | -20.00K | 712.00K | -1.59M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -1.77M | -4.90M | 4.48M | -1.90M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | -78.00K |
| (Increase) Decrease In Other Working Capital | -31.65M | -10.72M | -16.49M | -5.84M |
| Other Non-Cash Items | 4.14M | 3.83M | 2.71M | 2.88M |
| Net Cash From Continuing Operations | -34.20M | -23.74M | -34.82M | -41.76M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -34.20M | -23.74M | -34.82M | -41.76M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 101.12M | 149.72M | 154.13M | 32.10M |
| Purchases of Property, Plant & Equipment | -117.00K | -594.00K | -357.00K | -660.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -121.50M | -185.97M | -91.48M | -94.09M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -20.49M | -36.85M | 62.29M | -62.65M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 57.93M | 51.22M | 835.00K | 718.00K |
| Repayment of Long-Term Debt | 0.00 | 0.00 | -44.40M | -1.65M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 57.93M | 51.22M | -43.56M | -932.00K |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 3.23M | -9.36M | -16.09M | -105.34M |
Portfolios with ARQL
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserD-ZYRE
- User2012 picks 10/28/20121
- ContributorBreakout Stocks Of The Week...
- Contributor22 Biopharma Stocks With Br...
Latest ARQL Headlines from TheStreet
- 5 Under-$10 Stocks Setting Up to Trade Higher 11.30.12 | 12:11 pm
- 5 Stocks Poised for Breakouts 10.26.12 | 01:10 pm
- Stocks Drop on Eurozone, Earnings Anxieties 10.02.12 | 02:10 pm
- Arqule Shutters Lung Cancer Study Early Due to Futility 10.02.12 | 07:10 am
- Arqule Shares Slide on Lung Cancer Drug Safety Concern 08.29.12 | 10:08 am
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- 3 Stocks Under $10 Moving Higher 04.03.12 | 12:04 pm
Press Releases for ARQL
- ArQule Reports Fiscal 2012 Year End And Fourth Quarter Results - Business Wire 03.14.13 | 07:03 am
- ArQule To Report Fiscal 2012 Financial Results On March 14, 2013 - Business Wire 03.07.13 | 08:03 am
- ArQule, Inc. To Present At Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.27.13 | 08:02 am
- ArQule, Inc. To Present At RBC Capital Markets Global Healthcare Conference - Business Wire 02.19.13 | 08:02 am
- ArQule, Inc. To Present At Leerink Swann Global Healthcare Conference - Business Wire 02.07.13 | 08:02 am
- Daiichi Sankyo And ArQule Enroll First Hepatocellular Carcinoma Patient Into Global Phase 3 Trial For Tivantinib - Business Wire 01.31.13 | 08:01 am
- Daiichi Sankyo And ArQule Announce Top-Line Results Of Phase 2 Trial With Tivantinib In Colorectal Cancer - Business Wire 01.11.13 | 07:01 am
- ArQule Enrolls First Patient In Phase 1 Trial With ARQ 087, An FGFR Inhibitor - Business Wire 12.13.12 | 08:12 am
- ArQule, Inc. To Present At Oppenheimer Healthcare Conference - Business Wire 12.05.12 | 04:12 pm
- ArQule, Inc. To Present At Lazard Healthcare Conference - Business Wire 11.07.12 | 08:11 am
Partner Headlines for ARQL
- ArQule Earnings: Everything You Must Know Now - Wall St. Cheat Sheet 05.08.13 | 10:05 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 10.03.12 | 09:10 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 08.07.12 | 09:08 am
- Teradyne DROPS 16% in Recent Weeks and 4 Fresh Analyst Insights - Wall St. Cheat Sheet 07.06.12 | 01:07 pm
- Five Stocks With Heavy Insider Trading - Benzinga 06.11.12 | 01:06 pm
- Stock Insights: Dendreon, Medtronic, FedEx, ArQule, Rentrak June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- ArQule Announces Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma - Benzinga 06.02.12 | 06:06 pm
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seeking Alpha 05.25.12 | 08:05 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 05.01.12 | 09:05 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 04.02.12 | 09:04 am
